









Markets
/
Stocks
/
nasdaq-capr
/

Capricor Therapeutics Inc

CAPR

24.720USD

+1.690+7.34%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.13BMarket Cap

LossP/E TTM



Capricor Therapeutics Inc

24.720

+1.690+7.34%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Capricor Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Capricor Therapeutics Inc's fundamentals are relatively weak, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.80.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Capricor Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

128 / 392

Overall Ranking

266 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Capricor Therapeutics Inc Highlights

StrengthsRisks

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 772.85% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 22.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 22.27M.

Undervalued

The company’s latest PE is -14.14, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 14.69M shares, increasing 0.05% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 3.78K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.09.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

50.800

Target Price

+120.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Capricor Therapeutics Inc is 5.67, ranking 338 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 95.68%.

Score

Industry at a Glance

Previous score

5.67

Change



Financials

3.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.68

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.16

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Capricor Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Capricor Therapeutics Inc is 5.77, ranking 364 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -14.14, which is -83.36% below the recent high of -2.35 and -51.61% above the recent low of -21.43.

Score

Industry at a Glance

Previous score

5.77

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 128/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Capricor Therapeutics Inc is 8.40, ranking 124 out of 392 in the Biotechnology & Medical Research industry. The average price target is 47.50, with a high of 62.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

50.800

Target Price

+120.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Capricor Therapeutics Inc

CAPR

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Capricor Therapeutics Inc is 9.32, ranking 20 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 26.93 and the support level at 21.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.40

Change

1.92

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.113

Neutral

RSI(14)

53.707

Neutral

STOCH(KDJ)(9,3,3)

76.478

Buy

ATR(14)

1.490

Low Volatility

CCI(14)

84.307

Neutral

Williams %R

21.121

Buy

TRIX(12,20)

-0.374

Sell

StochRSI(14)

84.127

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

24.044

Buy

MA10

23.343

Buy

MA20

23.781

Buy

MA50

23.866

Buy

MA100

15.146

Buy

MA200

12.099

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Capricor Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.00%, representing a quarter-over-quarter decrease of 13.89%. The largest institutional shareholder is The Vanguard, holding a total of 2.56M shares, representing 5.60% of shares outstanding, with 13.53% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Nippon Shinyaku Co Ltd

7.09M

+230.41%

BlackRock Institutional Trust Company, N.A.

2.66M

-2.37%

The Vanguard Group, Inc.

Star Investors

2.21M

-3.93%

Geode Capital Management, L.L.C.

961.57K

-0.16%

State Street Investment Management (US)

801.34K

-45.36%

J. Goldman & Co., L.P.

481.98K

DG Capital Management, LLC

470.33K

Morgan Stanley & Co. LLC

449.61K

-2.90%

Two Sigma Investments, LP

430.00K

+98.65%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Capricor Therapeutics Inc is 1.37, ranking 322 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Capricor Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.